Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tyrosine kinase inhibitors
Drug Delivery
EyePoint reports Duravyu trial fail, raising questions
Targeting a major market in retinal diseases, EyePoint has revealed that its lead candidate failed to meet its primary endpoint in a phase 2 trial.
Eric Sagonowsky
May 6, 2024 10:55am
FDA rejects Xspray's would-be rival to BMS leukemia med Sprycel
Jul 11, 2023 9:55am